None listed
Conditions
Interventions
Medical Device : This clinical trial is designed without a control group and adopts a self-controlled case series design. In other words, the investigational medical device non-exposure period, define
Sponsors
Tau Medical
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects who meet all of the following criteria will be enrolled: 1) Adults aged 18 years or older at the time of screening. 2) Subjects who have received appropriate medical treatment (diuretics/medical therapy) for tricuspid regurgitation for at least 1 month prior to participation in this clinical trial. 3) Subjects who, at the screening visit, are assessed by transthoracic echocardiography (TTE) to have functional tricuspid regurgitation severity of Massive (4+) or greater, as defined by Tricuspid Valve Academic Research Consortium classification, and who have clinical symptoms corresponding to New York Heart Association (NYHA) functional class II or higher. 4) Subjects who, at the screening visit, are found on TTE or cardiac computed tomography (CT) to have a right ventricle (RV) larger than the left ventricle (LV). 5) Subjects who, at the screening visit, are found on cardiac CT to have an annular diameter of 40 mm or greater. 6) Subjects for whom the Heart Team, consisting of at least one cardiologist (specialist in cardiology) and at least one cardiac surgeon, has determined that surgical treatment for isolated Tricuspid Regurgitation is required. 7) Subjects who voluntarily decide to participate in this clinical trial and provide written informed consent on the subject consent form. 8) Subjects who are able to understand and comply with the investigator’s instructions and participate throughout the entire clinical trial period.
Exclusion criteria
Exclusion criteria: Subjects who meet any of the following criteria will be excluded: 1) Subjects in whom thrombus or embolic material is identified on echocardiography or cardiac computed tomography (CT) performed at the screening visit. 2) Subjects who have uncorrected coagulation disorders as shown by clinical laboratory tests performed at the screening visit. 3) Subjects who cannot use anticoagulant agents. 4) Subjects who, prior to participation in this clinical trial, have experienced major bleeding due to the use of anticoagulants (minor bleeding such as controllable epistaxis does not apply) requiring treatment, or who have had severe anemia necessitating hospitalization. 5) Subjects who, prior to participation in this clinical trial, have had devices such as an implantable cardioverter defibrillator (ICD) or a pacemaker implanted. 6) Subjects who, based on echocardiography and cardiac CT performed at the screening visit, are judged by the investigator to have anatomical structures unsuitable for implantation of the investigational medical device. 7) Subjects who, based on clinical laboratory tests performed at the screening visit, have a platelet count of =80,000/µL. 8) Subjects who, based on echocardiography performed at the screening visit, have pulmonary hypertension with TR Vmax =3.5 m/s. 9) Subjects who, based on echocardiography performed at the screening visit, have left ventricular ejection fraction (LVEF) <50%. 10) Subjects who, within 3 months prior to participation in this clinical trial, have had active gastrointestinal bleeding or have undergone gastrointestinal procedures (subjects with a risk of gastrointestinal bleeding). 11) Subjects who, within 30 days prior to participation in this clinical trial, have a history of cerebrovascular accident (CVA) or transient ischemic attack (TIA). 12) Subjects who, within 30 days prior to participation in this clinical trial, have a history of myocardial infarction (MI). 13) Subjects with active infective endocarditis requiring antibiotic therapy. 14) Subjects with severe terminal illnesses (e.g., malignant tumors, end-stage pulmonary disease, end-stage liver disease, end-stage renal failure). 15) Subjects who, based on echocardiography performed at the screening visit, have moderate or severe aortic, pulmonary, or mitral stenosis. 16) Subjects who, based on echocardiography performed at the screening visit, are found to have calcification of the tricuspid valve leaflets that would affect the procedure. 17) Subjects who, based on echocardiography performed at the screening visit, are found to have masses, thrombi, or proliferative lesions in the right heart system, femoral vein, or inferior vena cava. 18) Subjects who, within 30 days prior to participation in this clinical trial, have participated in another clinical trial. 19) Pregnant or lactating women, and women planning to become pregnant during the study period. 20) Women of childbearing potential who are not using medically acceptable methods of contraception.* * Medically acceptable methods of contraception include: (1) hormonal contraceptives, (2) implantation of an intrauterine device or intrauterine system, (3) dual barrier method [simultaneous use of a male condom and a cap (diaphragm or cervical cap)], (4) sterilization procedures (vasectomy, bilateral tubal ligation, etc.). 21) Subjects who, in addition to the above, are deemed by the investigator to have clinically significant findings that make them inappropriate for participati
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of subjects achieving at least a 1-grade improvement in tricuspid regurgitation (TR grade) according to Tricuspid Valve Academic Research Consortium definitions | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical improvement : Tricuspid Regurgitation grade, Kansas City Cardiomyopathy Questionnaire-12, estimated Glomerular Filtration Rate, edema score, New York Heart Association functional class, echocardiographic parameters;Anatomical improvement : right ventricular volume, tricuspid valve annulus area, and other CT core lab analysis parameters;Performance condition after removal (functional improvement): Effective Regurgitant Orifice Area, Vena Contracta Width, annulus area, cardiac dimension, Tricuspid Annular Plane Systolic Excursion, and other core lab analysis parameters;Long-term performance condition after removal (functional improvement) : Kansas City Cardiomyopathy Questionnaire-12, estimated Glomerular Filtration Rate, edema score, New York Heart Association functional class, echocardiographic parameters | — |
Countries
Korea, Republic of
Contacts
Public ContactGeu-Ru Hong
Yonsei University Health System, Severance Hospital
Outcome results
None listed